Feng‐Zhi Suo

639 total citations
19 papers, 554 citations indexed

About

Feng‐Zhi Suo is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Feng‐Zhi Suo has authored 19 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Feng‐Zhi Suo's work include Epigenetics and DNA Methylation (11 papers), Histone Deacetylase Inhibitors Research (9 papers) and Cancer-related gene regulation (7 papers). Feng‐Zhi Suo is often cited by papers focused on Epigenetics and DNA Methylation (11 papers), Histone Deacetylase Inhibitors Research (9 papers) and Cancer-related gene regulation (7 papers). Feng‐Zhi Suo collaborates with scholars based in China, Netherlands and New Zealand. Feng‐Zhi Suo's co-authors include Yi‐Chao Zheng, Bin Yu, Hong‐Min Liu, Hong‐Min Liu, Zhongrui Li, Shuai Wang, Xiaohan Yuan, Wim J. Quax, Zhonghua Li and Taoqian Zhao and has published in prestigious journals such as European Journal of Medicinal Chemistry, Journal of Cellular Biochemistry and Current Medicinal Chemistry.

In The Last Decade

Feng‐Zhi Suo

19 papers receiving 546 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feng‐Zhi Suo China 14 414 132 82 38 35 19 554
Xing‐Jie Dai China 12 292 0.7× 126 1.0× 58 0.7× 20 0.5× 21 0.6× 22 435
Christopher G. Nasveschuk United States 14 403 1.0× 304 2.3× 98 1.2× 29 0.8× 16 0.5× 24 667
Weiyan Cheng China 13 304 0.7× 113 0.9× 144 1.8× 39 1.0× 15 0.4× 25 499
Silvia Belluti Italy 14 360 0.9× 61 0.5× 73 0.9× 97 2.6× 28 0.8× 26 548
Antonella Pepe United States 13 264 0.6× 228 1.7× 108 1.3× 28 0.7× 56 1.6× 25 550
Yuya Oguro Japan 11 263 0.6× 205 1.6× 99 1.2× 11 0.3× 26 0.7× 15 450
Kristen L. Arienti United States 8 210 0.5× 117 0.9× 82 1.0× 26 0.7× 29 0.8× 8 364
Yong‐Cheng Ma China 13 275 0.7× 344 2.6× 53 0.6× 32 0.8× 10 0.3× 19 630
Alison E. McGonagle United Kingdom 9 329 0.8× 181 1.4× 125 1.5× 18 0.5× 15 0.4× 11 492
Kianga Schmuck Germany 10 268 0.6× 195 1.5× 58 0.7× 24 0.6× 18 0.5× 11 414

Countries citing papers authored by Feng‐Zhi Suo

Since Specialization
Citations

This map shows the geographic impact of Feng‐Zhi Suo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng‐Zhi Suo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng‐Zhi Suo more than expected).

Fields of papers citing papers by Feng‐Zhi Suo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng‐Zhi Suo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng‐Zhi Suo. The network helps show where Feng‐Zhi Suo may publish in the future.

Co-authorship network of co-authors of Feng‐Zhi Suo

This figure shows the co-authorship network connecting the top 25 collaborators of Feng‐Zhi Suo. A scholar is included among the top collaborators of Feng‐Zhi Suo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng‐Zhi Suo. Feng‐Zhi Suo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Zhao, Chunlong, Deng Chen, Feng‐Zhi Suo, et al.. (2023). Discovery of highly potent HDAC8 PROTACs with anti-tumor activity. Bioorganic Chemistry. 136. 106546–106546. 21 indexed citations
2.
Zhao, Chunlong, Deng Chen, Feng‐Zhi Suo, et al.. (2023). Discovery of Highly Potent Hdac8 Protacs with Anti-Tumor Activity. SSRN Electronic Journal. 1 indexed citations
3.
Suo, Feng‐Zhi, et al.. (2022). Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery. Pharmaceutics. 14(2). 395–395. 21 indexed citations
4.
Suo, Feng‐Zhi, et al.. (2022). Receptor Specificity Engineering of TNF Superfamily Ligands. Pharmaceutics. 14(1). 181–181. 9 indexed citations
5.
Li, Zhongrui, Feng‐Zhi Suo, Dandan Shen, et al.. (2020). Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation. Bioorganic Chemistry. 97. 103648–103648. 39 indexed citations
6.
Li, Zhongrui, Ting Ma, Bo Hu, et al.. (2019). Sanggenon O induced apoptosis of A549 cells is counterbalanced by protective autophagy. Bioorganic Chemistry. 87. 688–698. 5 indexed citations
7.
Li, Zhonghua, Lina Ding, Zhongrui Li, et al.. (2019). Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A). Acta Pharmaceutica Sinica B. 9(4). 794–808. 69 indexed citations
8.
Wang, Shuai, et al.. (2019). Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors. European Journal of Medicinal Chemistry. 167. 388–401. 52 indexed citations
9.
Suo, Feng‐Zhi, Yali Feng, Lili Song, et al.. (2019). Synthesis and biological evaluation of vanadium complexes as novel anti-tumor agents. European Journal of Medicinal Chemistry. 176. 1–10. 36 indexed citations
10.
Liu, Hong‐Min, Feng‐Zhi Suo, Xiaobo Li, et al.. (2019). Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors. European Journal of Medicinal Chemistry. 175. 357–372. 33 indexed citations
11.
Li, Zhongrui, Shuai Wang, Linlin Yang, et al.. (2019). Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors. European Journal of Medicinal Chemistry. 166. 432–444. 36 indexed citations
12.
Zhao, Li‐Juan, Ting Zhang, Xuejian Feng, et al.. (2018). USP28 contributes to the proliferation and metastasis of gastric cancer. Journal of Cellular Biochemistry. 120(5). 7657–7666. 25 indexed citations
13.
Li, Zhongrui, Feng‐Zhi Suo, Bo Hu, et al.. (2018). Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor. Bioorganic Chemistry. 84. 164–169. 38 indexed citations
14.
Zhang, Ting, Feng‐Zhi Suo, Jiao Chang, et al.. (2018). Lysine‐specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC‐803. Journal of Cellular Biochemistry. 119(6). 4957–4966. 13 indexed citations
15.
Shen, Dandan, et al.. (2018). Development of formaldehyde dehydrogenase-coupled assay and antibody-based assays for ALKBH5 activity evaluation. Journal of Pharmaceutical and Biomedical Analysis. 162. 9–15. 12 indexed citations
16.
Duan, Ying‐Chao, Feng‐Zhi Suo, Xiaoyu Zhai, et al.. (2018). Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy. Bioorganic & Medicinal Chemistry. 26(23-24). 6000–6014. 34 indexed citations
17.
Sun, Kai, et al.. (2017). Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation. Bioorganic & Medicinal Chemistry Letters. 27(22). 5036–5039. 30 indexed citations
18.
Zheng, Yi‐Chao, Jiao Chang, Ting Zhang, et al.. (2017). An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors. Current Medicinal Chemistry. 24(23). 2496–2504. 18 indexed citations
19.
Li, Zhonghua, Xue‐qi Liu, Peng Geng, et al.. (2017). Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors. ACS Medicinal Chemistry Letters. 8(4). 384–389. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xing‐Jie Dai Breakdown of academic impact, for papers by Christopher G. Nasveschuk Breakdown of academic impact, for papers by Weiyan Cheng Breakdown of academic impact, for papers by Silvia Belluti Breakdown of academic impact, for papers by Antonella Pepe Breakdown of academic impact, for papers by Yuya Oguro Breakdown of academic impact, for papers by Kristen L. Arienti Breakdown of academic impact, for papers by Yong‐Cheng Ma Breakdown of academic impact, for papers by Alison E. McGonagle Breakdown of academic impact, for papers by Kianga Schmuck
Rankless by CCL
2026